| scholarly article | Q13442814 |
| P50 | author | Nirmala Kampan | Q57025562 |
| P2093 | author name string | Andrew N Stephens | |
| Magdalena Plebanski | |||
| Michael A Quinn | |||
| Orla M McNally | |||
| Mutsa Tatenda Madondo | |||
| P2860 | cites work | Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin | Q24299103 |
| Foxp3 occupancy and regulation of key target genes during T-cell stimulation | Q24623384 | ||
| A concise history of gout and hyperuricemia and their treatment | Q24633751 | ||
| Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer | Q26746203 | ||
| CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients | Q27692628 | ||
| RIP off STAT3 to counteract tumor progression | Q52758657 | ||
| Immunotherapeutic Interleukin-6 or Interleukin-6 receptor blockade in cancer: challenges and opportunities | Q53163338 | ||
| Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells | Q53545523 | ||
| Ovarian cancer | Q54105461 | ||
| Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients | Q56895649 | ||
| The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells | Q82601455 | ||
| Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity | Q84364955 | ||
| Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors | Q84501943 | ||
| Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study | Q86075907 | ||
| Suppressive activity of human regulatory T cells is maintained in the presence of TNF | Q87022519 | ||
| Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients | Q87734082 | ||
| Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma | Q27853285 | ||
| Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells | Q27860460 | ||
| Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis | Q28118730 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| The future of immune checkpoint therapy | Q28259862 | ||
| TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells | Q28296956 | ||
| Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression | Q28593882 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| PD-L1 regulates the development, maintenance, and function of induced regulatory T cells | Q30080038 | ||
| Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice | Q30793383 | ||
| Functional Gene Analysis Reveals Cell Cycle Changes and Inflammation in Endothelial Cells Irradiated with a Single X-ray Dose | Q33602008 | ||
| The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer | Q33650479 | ||
| Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients | Q33754724 | ||
| Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients | Q33914512 | ||
| FOXP3: not just for regulatory T cells anymore | Q34593657 | ||
| Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. | Q34985717 | ||
| Cytokine induction of tumor necrosis factor receptor 2 is mediated by STAT3 in colon cancer cells | Q35626872 | ||
| Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth | Q35824820 | ||
| TNF downmodulates the function of human CD4+CD25hi T-regulatory cells | Q35849817 | ||
| Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer | Q35908928 | ||
| Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. | Q36358324 | ||
| TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. | Q36553796 | ||
| Interleukin-6: discovery of a pleiotropic cytokine | Q36561156 | ||
| Mechanisms of transcoelomic metastasis in ovarian cancer. | Q36643128 | ||
| Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling | Q36685345 | ||
| PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient | Q36882550 | ||
| Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma | Q36908883 | ||
| IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer | Q36963605 | ||
| IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells | Q36985100 | ||
| Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research | Q37196532 | ||
| TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40 | Q37197918 | ||
| Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. | Q37236554 | ||
| TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis | Q37236581 | ||
| The effects of IL-6 on CD4 T cell responses | Q37290719 | ||
| Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer | Q37466140 | ||
| Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells | Q37511971 | ||
| Regulatory T cells: how do they suppress immune responses? | Q37593768 | ||
| Prognostic value of PDL1 expression in pancreatic cancer | Q37687595 | ||
| IL-6: regulator of Treg/Th17 balance | Q37768101 | ||
| Inflammation and ovarian cancer | Q37986362 | ||
| Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. | Q38010509 | ||
| Th17 and regulatory T cell balance in autoimmune and inflammatory diseases | Q38177967 | ||
| Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. | Q38305613 | ||
| IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model | Q38714105 | ||
| Polysaccharide peptides from Coriolus versicolor exert differential immunomodulatory effects on blood lymphocytes and breast cancer cell line MCF-7 in vitro. | Q38777258 | ||
| Interleukins 1 and 6 as Main Mediators of Inflammation and Cancer. | Q38853516 | ||
| Targeting Inflammation in Cancer Prevention and Therapy | Q39027675 | ||
| Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis | Q39198945 | ||
| Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy | Q39337489 | ||
| Cytokine Signaling in the Development and Homeostasis of Regulatory T cells | Q39376990 | ||
| Global trends and predictions in ovarian cancer mortality. | Q39420632 | ||
| Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. | Q39696464 | ||
| Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications | Q40416586 | ||
| Interleukin-6 in biology and medicine | Q40850225 | ||
| IL-6 production by human T lymphocytes. Expression in HTLV-1-infected but not in normal T cells. | Q41699395 | ||
| IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer. | Q42139657 | ||
| Homogeneous expansion of human T-regulatory cells via tumor necrosis factor receptor 2 | Q42241730 | ||
| TNFR2 Expression on CD25(hi)FOXP3(+) T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing Effectors | Q42538920 | ||
| Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment | Q43846991 | ||
| Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. | Q45283850 | ||
| Cutting edge: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. | Q45998381 | ||
| Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape | Q46129475 | ||
| Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy | Q46217068 | ||
| IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients | Q47974482 | ||
| Upregulation of Treg-Related Genes in Addition with IL6 Showed the Significant Role for the Distant Metastasis in Colorectal Cancer. | Q49175582 | ||
| Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma | Q50909597 | ||
| Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators. | Q51127034 | ||
| Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells | Q51128749 | ||
| Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts. | Q51250934 | ||
| Old dog, new tricks: IL-6 cluster signaling promotes pathogenic TH17 cell differentiation | Q51255626 | ||
| Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells. | Q51384283 | ||
| Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine Type I Interferon Loop. | Q51487509 | ||
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 1482 | |
| P577 | publication date | 2017-11-06 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells | |
| P478 | volume | 8 |
| Q89884171 | Mediation Analysis Reveals Potential Biological Mechanism of Ascites Influencing Recurrence in Patients with Epithelial Ovarian Cancer |
| Q90397109 | Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells |
| Q58753360 | Polyphenols in Liubao Tea Can Prevent CCl₄-Induced Hepatic Damage in Mice through Its Antioxidant Capacities |
| Q55074144 | TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors. |
| Q88868526 | TNF-R2 in tumor microenvironment as prognostic factor in epithelial ovarian cancer |
| Q61447405 | Tumor Necrosis Factor and Regulatory T Cells |
Search more.